Texas Permanent School Fund Corp Boosts Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Texas Permanent School Fund Corp grew its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 18.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 38,626 shares of the company’s stock after purchasing an additional 5,922 shares during the period. Texas Permanent School Fund Corp owned approximately 0.08% of Amphastar Pharmaceuticals worth $1,545,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its position in shares of Amphastar Pharmaceuticals by 7.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 379,480 shares of the company’s stock valued at $23,471,000 after purchasing an additional 27,102 shares in the last quarter. Epoch Investment Partners Inc. grew its position in Amphastar Pharmaceuticals by 348.7% in the fourth quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company’s stock worth $36,648,000 after acquiring an additional 460,473 shares during the period. TD Asset Management Inc grew its position in Amphastar Pharmaceuticals by 449.0% in the fourth quarter. TD Asset Management Inc now owns 793,559 shares of the company’s stock worth $49,082,000 after acquiring an additional 649,001 shares during the period. Silvercrest Asset Management Group LLC grew its position in Amphastar Pharmaceuticals by 35.1% in the first quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock worth $4,937,000 after acquiring an additional 29,182 shares during the period. Finally, US Bancorp DE grew its position in Amphastar Pharmaceuticals by 2,648.8% in the fourth quarter. US Bancorp DE now owns 21,248 shares of the company’s stock worth $1,314,000 after acquiring an additional 20,475 shares during the period. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Floyd F. Petersen sold 3,000 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the transaction, the director now owns 75,409 shares of the company’s stock, valued at $3,504,256.23. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Floyd F. Petersen sold 3,000 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $46.47, for a total transaction of $139,410.00. Following the transaction, the director now owns 75,409 shares of the company’s stock, valued at $3,504,256.23. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO William J. Peters sold 10,282 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total value of $454,772.86. Following the transaction, the chief financial officer now directly owns 94,103 shares in the company, valued at approximately $4,162,175.69. The disclosure for this sale can be found here. Insiders have sold a total of 37,979 shares of company stock valued at $1,671,307 over the last quarter. 27.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on AMPH shares. Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a research report on Thursday, August 8th. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Finally, StockNews.com cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, September 12th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $63.00.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $49.78 on Thursday. The stock’s 50-day moving average is $44.14 and its two-hundred day moving average is $42.60. The firm has a market cap of $2.43 billion, a price-to-earnings ratio of 17.22, a PEG ratio of 0.85 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.63 and a current ratio of 3.52.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.75 by $0.10. The company had revenue of $182.39 million for the quarter, compared to analyst estimates of $171.29 million. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. Analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.